Orbillion has successfully scaled its cultivated beef production across North America, Europe, and Asia.
This milestone cements Orbillion's leadership in advancing sustainable food technology and overcoming barriers that so far have hindered the commercial production of cultivated meat. Orbillion is also announcing the addition of food industry veteran Dr. Thomas, a veteran from Nestlé and DSM, Beck to its Board of Directors, bolstering its path to revenue.
This fall, Dr. Bubner has been sharing Orbillion’s groundbreaking technical advancements on global stages, including NY Climate Week, GITEX in Dubai, and Slush in Helsinki. These platforms have highlighted the company’s leadership in redefining bioprocesses for food production, and its commitment to making cultivated meat commercially viable at a global level. Unlike other companies that rely on fibroblasts or require genetic modification or other laborious processes to adapt cells for production, Orbillion is the only company scaling real muscle and fat cells without genetic modification (non-GMO). With their revolutionary “bioware” they eliminate the need for time-intensive cell adaptation or modification processes, thus allowing cells to go directly from biopsy to scale-up. This is dramatically accelerating the path to product—and to market—while reducing development costs by up to $11M and development time by nearly one and a half years.
“This achievement is revolutionary—not just for Orbillion, but for the future of food,” said Samet Yildirim, CTO of Orbillion. “Direct scaling of beef muscle and fat cells—the very building blocks of meat—without GMO, serum or expensive growth factors, allows us to deliver the most tasty, sustainable, and cost-effective cultivated meat the world has ever seen.”
Overcoming the Biggest Hurdles in Cultivated Meat
The commercialization of cultivated meat faces significant hurdles, particularly the reliance on bioprocesses originally designed for biopharmaceuticals, which are unsuitable for the volumes and cost structures required for food production. These processes are ill-suited for scaling at the volumes and costs required to transform the global food system. Orbillion is uniquely equipped to address these challenges thanks to three core advantages:
Real Muscle and Fat Cells: Orbillion’s breakthrough technology directly scales non-GMO muscle and fat cells using their revolutionary “bioware” driven by advanced computational models and AI. This ensures faster cultivated meat production at a lower cost (up to 18 months faster and up to $11M in saved cost).
Biopharma Expertise: With hands-on experience in biopharma scale-up, Orbillion’s co-founders have reimagined bioprocesses specifically for food production, massively optimizing efficiency and reducing costs.
Controlled Cellular Microenvironment: Using their “bioware” supported by advanced computational models, Orbillion is able to tightly control the microenvironment needed for cell growth. Thus, Orbillion supercharges production without relying on expensive growth factors, setting a new benchmark for affordability and scalability.
Comments